Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease PharmaTimesSubcutaneous delivery shows IVlevel efficacy in moderate to severe TEDClinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story Post navigation Previous: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing ChangesNext: Kennedy changes vaccine panel charter after legal setback Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026